Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II atezolizumab + bevacizumab in PD-L1 high non-squamous NSCLC (WJOG10718L)
jRCT2080223980Phase 2Completed
- Sponsor
- Takashi Seto (Coordinating Investigator)
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and bevacizumab in Non-small cell lung cancer (NS-NSCLC), sponsored by Takashi Seto (Coordinating Investigator). Started Jul 2018; status: completed.
02
Drugs
atezolizumabbevacizumab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on jRCT2080223980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223980.